Patient Information Leaflets (PILs)
These Patient Information Leaflets (PILs) are specially written by the British Association of Dermatologists (BAD).
There are thousands of different skin complaints, therefore, the focus of the British Association of Dermatologists' PILs production is on the most common, rarest or debilitating skin conditions.
The offer to provide details of source materials used to inform the British Association of Dermatologists' PILs is for instances where the advice provided in the PILs does not reflect local practice and therefore evidence supporting said advice needs to be produced. It is not an offer to conduct literature searches or supply bibilographic materials for your own research.
For the latest BAD advice on Covid-19 for patients, please check the News and Media section of the website. Find this here. Our information for healthcare professionals is here.
Rituximab is a medicine known as a biological therapy or ‘biologic’. It reduces the number of a type of blood cell which defends the body against infection. These are known as immune cells or B cells. Rituximab does this by binding to a protein called CD20 on their surface. B cells can cause diseases known as inflammatory and autoimmune conditions. B cells do this by producing harmful autoantibodies. Autoantibodies are proteins produced by the immune system against our own tissues and cause inflammation. By removing B cells, autoantibody levels are reduced, and inflammation and its effects can be reduced.